Cancer Research and Treatment

Volume 34(4); August 2002

Original Articles

Analysis of Local Recurrence Following Proximal Gastrectomy in Patients with Upper Third Gastric Cancer: Chang Hak Yoo, Byung Ho Sohn, Won Kon Han, Won Kil Pae; Cancer Res Treat. 2002;34(4):247-251. Published online August 31, 2002; DOI: https://doi.org/10.4143/crt.2002.34.4.247

PURPOSE
Little is known about local recurrence following proximal gastrectomy in patients with upper third gastric cancer. We performed this study to evaluate the long-term results of a proximal gastrectomy, and to analyze the risk factors of local recurrence affecting survival in these patients.
MATERIALS AND METHODS
We undertook a retrospective study of 63 patients who underwent potentially curative proximal gastrectomy between 1990 and 1999, with special reference to local recurrence.
RESULTS
During a median follow-up period of 37 months, 25 of the 63 patients (39.7%) developed a recurrence of cancer, with local recurrence in 15 patients (23.8%), the majority of these occurring at the remnant stomach or anastomosis. The median time to local recurrence was 38 months (8~78 months). Univariate analysis of risk factors for local recurrence revealed an infiltrative or diffuse gross type, with a tumor sizes>5 cm, a distal resection margin CONCLUSION
When performing a proximal gastrectomy for upper third gastric cancer, even after curative resection, all risk factors should be considered to reduce rates of local recurrence.

Citations

Citations to this article as recorded by

Clinicopathologic characteristics in patients with upper third gastric cancer following radical surgical treatment
Xiaoming Ma, Wei Zhou, Cheng Wang, Wei Miao, Ning Liu, Shigui Wang, Shihao Guan
Medicine.2018; 97(45): e13017. CrossRef
Recurrence Following Laparoscopy-Assisted Gastrectomy for Gastric Cancer: A Multicenter Retrospective Analysis of 1,417 Patients
Jyewon Song, Hyuk-Joon Lee, Gyu Seok Cho, Sang-Uk Han, Min-Chan Kim, Seung Wan Ryu, Wook Kim, Kyo Young Song, Hyung-Ho Kim, Woo Jin Hyung
Annals of Surgical Oncology.2010; 17(7): 1777. CrossRef
Proximal Gastrectomy Reconstructed by Jejunal Pouch Interposition for Upper Third Gastric Cancer: Prospective Randomized Study
Chang Hak Yoo, Byung Ho Sohn, Won Kon Han, Won Kil Pae
World Journal of Surgery.2005; 29(12): 1592. CrossRef
Issues in the Management of the Upper Third Gastric Cancer
Han-Kwang Yang
Cancer Research and Treatment.2004; 36(1): 4. CrossRef

3,840 View
21 Download
4 Crossref

Expression of Cyclooxygenase-2 Protein in Gastric Carcinogenesis: Seoung Wan Chae, Jin Hee Sohn, Hyung Sik Shin, Young Euy Park; Cancer Res Treat. 2002;34(4):252-257. Published online August 31, 2002; DOI: https://doi.org/10.4143/crt.2002.34.4.252

Abstract PDF

PURPOSE
The increased expression of cyclooxygenase (COX)-2 has been implicated in the development and progression of human cancers. We investigated COX-2 expression in normal, gastric adenomas and adenocarcinomas.
MATERIALS AND METHODS
COX-2 protein was assayed in gastrectomy and biopsy specimens, from 68 gastric adenocarcinomas, 40 gastric adenomas and 35 normal gastric tissues, by immunohistochemistry, and 32 specimens of normal and adenocarcinomas by western blot analysis. Correlation between COX-2 expression and various clinicopathological factors were studied in the gastric adenocarcinoma.
RESULTS
COX-2 protein expression in epithelial cells was increased in 6/40 (15%) of the adenomas and 55/68 (80.9 %) of the adenocarcinomas, while normal mucosa was not expressed. COX-2 expression was increased in differ-entiated gastric carcinomas compared with those in the undifferentiated group (p<0.05). The expression of COX-2 protein was unrelated to tumor size, depth of tumor invasion and the presence of lymphatic or vascular invasions. Western blot analysis showed the enhanced expression of the COX-2 protein (23 out of 32)(71%) in gastric carcinomas compared to that of normal gastric mucosal epithelium.
CONCLUSION
The above results indicated that the expression of COX-2 protein occurs in dysplastic epithelium and gastric carcinomas, which suggests COX-2 expression may contribute to tumor formation.

Citations

Citations to this article as recorded by

Embellistatin, a microtubule polymerization inhibitor, inhibits angiogenesis both in vitro and in vivo
Hye Jin Jung, Joong Sup Shim, Hyang Burm Lee, Chang-Jin Kim, Takashi Kuwano, Mayumi Ono, Ho Jeong Kwon
Biochemical and Biophysical Research Communications.2007; 353(2): 376. CrossRef
Homoisoflavanone inhibits retinal neovascularization through cell cycle arrest with decrease of cdc2 expression
Jeong Hun Kim, Ki Hyun Kim, Jin Hyoung Kim, Young Suk Yu, Young-Myeong Kim, Kyu-Won Kim, Ho Jeong Kwon
Biochemical and Biophysical Research Communications.2007; 362(4): 848. CrossRef
Expression of Cyclooxygenase-2 and Bcl-2 in Human Gastric Adenomas
Jee Hyun Park, Kyung Hee Kang, Se Hwan Kim, Jong Hyup Lee, Chang Min Cho, Young Oh Kweon, Sung Kook Kim, Yong Hwan Choi, Han Ik Bae, Mi Sung Kim
The Korean Journal of Internal Medicine.2005; 20(3): 198. CrossRef
A New Curcumin Derivative, HBC, Interferes with the Cell Cycle Progression of Colon Cancer Cells via Antagonization of the Ca2+/Calmodulin Function
Joong Sup Shim, Jiyong Lee, Hyun-Ju Park, So-Jung Park, Ho Jeong Kwon
Chemistry & Biology.2004; 11(10): 1455. CrossRef
Expression of Cyclooxygenase (COX)-2 as a Prognostic Factor in Nasopharyngeal Cancer
Kyubo Kim, Hong-Gyun Wu, Suk Won Park, Chong Jai Kim, Charn Il Park
Cancer Research and Treatment.2004; 36(3): 187. CrossRef

4,600 View
25 Download
5 Crossref

Altered Retinoblastoma Protein Expression and Proliferative Activity in Urethane Induced Mouse Lung Tumorigenesis: Jin Haeng Chung, Ja June Jang, Min Jae Lee, Eul Keun Ham; Cancer Res Treat. 2002;34(4):258-263. Published online August 31, 2002; DOI: https://doi.org/10.4143/crt.2002.34.4.258

Abstract PDF

Lung cancer develops through a multistage process involving the accumulation of diverse genetic alterations. To gain an understanding of the roles played by tumor suppressor gene proteins and proliferating cell nuclear antigen (PCNA) in chemical carcinogen-induced mouse lung tumorigenesis, we examined the expression of retinoblastoma protein (Rb), p53, and PCNA in normal lung tissues and urethane-induced mouse lung tumors.
MATERIALS AND METHODS
ICR mice were given urethane by intra-peritoneal injection, and sacrificed at 5, 13, 21, 31, and 37 weeks following treatment. Sequential morphological changes and the immunohistochemical expression of Rb protein, p53, and (PCNA), during mouse lung tumorigenesis, were examined.
RESULTS
During the carcinogenesis, sequential histological changes from hyperplasia of type II pneumocytes, to adenomas, and ultimately to overt adenocarcinomas were noted. Intense nuclear staining of the Rb protein was observed in normal and hyperplastic alveolar epithelial cells and adenomas. In adenocarcinomas, the Rb protein expression was significantly diminished. The p53 mutant protein was not detected in any lesion. The PCNA labeling index increased along with the advance in the histological grade.
CONCLUSION
The above results indicate that mouse pulmonary adenocarcinomas develop through premalignant lesions, and down-regulation of the Rb protein expression may be implicated in the urethane-induced mouse lung tumorigenesis. In addition, the PCNA labeling index may reflect the malignant potential during the tumor progression.

Citations

Citations to this article as recorded by

Expression of Caspase 3, Survivin, and p53 Protein in Urethane Induced Mouse Lung Carcinogenesis
Jong Wook Shin, Soo Hwan Lee, Eon Sub Park
Tuberculosis and Respiratory Diseases.2007; 63(3): 251. CrossRef

3,341 View
19 Download
1 Crossref

The Effects of Irradiation on Lung Function in Patients with Lung Cancer: Kyung Hee Gang, Jae Yong Park, Kyung Rok Kim, Po Hee Chae, Nack Cheon Bae, Seung Ick Cha, Chang Ho Kim, Tae Hoon Jung; Cancer Res Treat. 2002;34(4):264-267. Published online August 31, 2002; DOI: https://doi.org/10.4143/crt.2002.34.4.264

Abstract PDF: This study was performed to assist in the prediction of the clinical tolerance of patients with lung cancer to irradiation.
MATERIALS AND METHODS
The changes in lung function of 26 patients with lung carcinomas, who had received radiation with curative intent, or postoperative adjuvant radiotherapy, were prospectively studied. Their pulmonary function tests were conducted at presentation, and then at 2 weeks, 2 months, and 6 months, following radiotherapy.
RESULTS
When the parameters of postirradiation pulmonary functions (2 weeks, 2 months and 6 months) were compared with the preirradiation baseline data, there was a statistically significant decrease in FEF25~75% at 2 months, but the rest of the parameters showed no significant change following irradiation. However, when the baseline lung function was compared with the lung function at the lowest FVC, in patients with curative radiotherapy, there was a statistically significant decrease of about 10% in the FEV1 and DLCO.
CONCLUSION
Preirradiation assessment of pulmonary functions, particularly the FEV1 and DLCO will be useful for the prediction of the clinical tolerance to irradiation.

4,277 View
18 Download

Expression of G1/S Phase Checkpoint Proteins in Breast Carcinoma: Relationship to Clinicopathologic Factors andSurvival Rate: Mi Ja Lee; Cancer Res Treat. 2002;34(4):268-273. Published online August 31, 2002; DOI: https://doi.org/10.4143/crt.2002.34.4.268

Abstract PDF: The retinoblastoma protein (pRb)/cyclin D1/ p16 pathway plays a critical role in controlling the progression from G1 to S phase of the cell cycle. Abnormal expression of the individual components of the pathway has been reported in many human cancers, including the breast. Our aim was to investigate the role of this pathway in tumorigenesis and tumor progression, and to evaluate the value of these oncoproteins as potential prognostic factors in breast cancer.
MATERIALS AND METHODS
We examined the significance of the p16, pRb, and cyclin D1 expression in 128 cases of invasive breast carcinomas using immunohistochemistry on formalin fixed, paraffin sections. The results correlated with the survival rate and clinicopathologic variables, including age, histologic grade, lymph node status, tumor size, estrogen receptor (ER) and progesterone receptor (PR) content. The negative finding for nuclear staining for pRb and p16 were defined as abnormal.
RESULTS
Abnormal expression of the p16 and pRb were seen in 21% and 43% of tumors, respectively. There was a significant inverse relationship between the p16 and pRb expressions. There was no association between the p16 staining and any other parameters, including survival rate, cyclin D1, or clinicopathologic variables. Surprisingly, there was a trend for pRb positive tumors to be grade III ductal carcinomas. Cyclin D1 positivity was noted in 46% of cases. The expression of cyclin D1 protein was significantly higher in lower histologic grades, and with higher ER and PR expressions.
CONCLUSION
These findings suggest the p16 may be negatively regulated by the pRb, and that cyclin D1 is involved in the tumor progression in well-differentiated tumors and could be an ER and PR related protein. In a Cox multivariate analysis, the p16, pRb, and cyclin D1 were not independent predictors of patient outcome.

3,436 View
15 Download

A Phase II Study of Gemcitabine Monotherapy in Breast Cancer Patients Refractory to Anthracycline and Taxane: Jun Yong Park, Chul Kim, Joo Hyuk Sohn, Yong Tae Kim, Sun Young Rha, Woo Ick Jang, Gwi Eon Kim, Hyun Cheol Chung; Cancer Res Treat. 2002;34(4):274-279. Published online August 31, 2002; DOI: https://doi.org/10.4143/crt.2002.34.4.274

Abstract PDF

We performed a phase II trial to evaluate the efficacy and the safety of gemcitabine monotherapy, a pyrimidine antimetabolite, in patients, who had previously failed anthracycline and taxane-based chemotherapy for the treatment of metastatic breast cancer.
MATERIALS AND METHODS
Twenty-one patients with metastatic breast cancer, which was unresponsive to previous chemotherapy, were entered into this study. Gemcitabine was administered at 850 mg/m2, as a 60- minute intravenous infusion on days 1, 8 and 15. This regimen was repeated every 28 days with G-CSF support, but without dose reduction.
RESULTS
Objective responses were seen in 6 of the 20 patients who were able to be evaluated (1 complete response and 5 partial responses), with an objective response rate of 30%. The median time to progression was 5 (1~20) months, and the median overall survival duration was 11 (2~21) months. The actual dose intensity was 566.7 mg/m2/wk (range; 340~637.5 mg/m2/wk) and the relative dose intensity was 0.89 (range; 0.40~1.00). Toxicity was mainly hematological. Toxicities included: grade 3 neutropenia in 20% and anemia in 5%. Grades 3 and 4 thrombocytopenia occurred in 15% of the patients.
CONCLUSION
Gemcitabine monotherapy is an effective and safe treatment for refractory breast cancer patients heavily treated with the anthracycline and taxane- based regimen.

Citations

Citations to this article as recorded by

A phase II study of tipifarnib and gemcitabine in metastatic breast cancer
Clinton Yam, Rashmi K. Murthy, Vicente Valero, Janio Szklaruk, Girish S. Shroff, Carol J. Stalzer, Aman U. Buzdar, James L. Murray, Wei Yang, Gabriel N. Hortobagyi, Stacy L. Moulder, Banu Arun
Investigational New Drugs.2018; 36(2): 299. CrossRef
Ribonucleotide reductase M1 (RRM1) 2464G>A polymorphism shows an association with gemcitabine chemosensitivity in cancer cell lines
Woo Sun Kwon, Sun Young Rha, Yeon Ho Choi, Jung Ok Lee, Kyu Hyun Park, Jae Joon Jung, Tae Soo Kim, Hei-Cheul Jeung, Hyun Cheol Chung
Pharmacogenetics and Genomics.2006; 16(6): 429. CrossRef
Gemcitabine Single or Combination Chemotherapy in Post Anthracycline and Taxane Salvage Treatment of Metastatic Breast Cancer: Retrospective Analysis of 124 Patients
Min Kyoung Kim, Sung-Bae Kim, Jin Hee Ahn, Soon Im Lee, Sei-Hyun Ahn, Byung Ho Son, Gyungyub Gong, Hak-Hee Kim, Jung-Shin Lee, Yoon-Koo Kang, Woo Kun Kim
Cancer Research and Treatment.2006; 38(4): 206. CrossRef
Gemcitabine monotherapy as salvage chemotherapy in heavily pretreated metastatic breast cancer
Sun Young Rha, Yong Hwa Moon, Hei Chul Jeung, Yong Tae Kim, Joo Hyuk Sohn, Woo Ick Yang, Chang Ok Suh, Gwi Eon Kim, Jae Kyung Roh, Hyun Cheol Chung
Breast Cancer Research and Treatment.2005; 90(3): 215. CrossRef

4,662 View
35 Download
4 Crossref

Pirarubicin, UFT, Leucovorin Chemotherapy in Non-embolizable and Transcatheter Arterial Chemoembolization-Failed Hepatocellular Carcinoma Patients; A Phase II Clinical Study: Kyong Hwa Park, So Young Yoon, Sang Cheul Oh, Jae Hong Seo, Chul Won Choi, Jong Eun Yeon, Byung Soo Kim, Sang Won Shin, Yeul Hong Kim, Kwan Soo Byun, Jun Suk Kim, Chang Hong Lee; Cancer Res Treat. 2002;34(4):280-283. Published online August 31, 2002; DOI: https://doi.org/10.4143/crt.2002.34.4.280

Abstract PDF: Hepatocellular carcinomas are one of the most common malignancies in the world. However, no effective therapeutic modality has been proven to prolong the survival of patients in an inoperable stage. The purpose of this study was to determine the response rate and the toxicities of a combination of pirarubicin, UFT and leucovorin in patients with non-embolizable hepatocellular carcinomas, or who had progressed during their transcatheter arterial chemoembolization treatment.
MATERIALS AND METHODS
Of 23 patients with a hepatocellular carcinoma, 11 had progressed during a transcatheter arterial chemoembolization, with the other 12 being transcatheter arterial chemoembolization-naive. All the patients were treated with pirarubicin (70 mg/m2 i.v., day 1), UFT (350 mg/m2 P.O., day 1~21), and leucovorin (25 mg/m2 P.O., day 1~21).
RESULTS
Twenty patients were able to be evaluated, with a partial response being achieved in four, giving an overall response rate of 20% (95% confidence interval, 7~44%). The median overall survival time was 6 months, and the median survival time of the transcatheter arterial chemoembolization-naive patients was significantly longer than that of those treated by transcatheter arterial chemoembolization (p=0.012). The most significant dose-limiting toxicity was leucopenia and thrombocytopenia.
CONCLUSION
The combination of pirarubicin, UFT and leucovorin therapies showed marginal antitumor activity and significant toxicity in patients with non-embolizable or failed transcatheter arterial chemoembolization hepatocellular carcinomas.

4,352 View
17 Download

Treatment Outcome of Brain Metastasis after the Cranial Radiotherapy Followed by Fractionated Stereotactic Radiotherapy and Its Prognostic Factors: Hak Jae Kim, Semie Hong, Suzy Kim, Jin Ho Kim, Il Han Kim, Charn Il Park, Sung Whan Ha, Hong Gyun Wu, Wee Saing Kang; Cancer Res Treat. 2002;34(4):284-288. Published online August 31, 2002; DOI: https://doi.org/10.4143/crt.2002.34.4.284

Abstract PDF

To evaluate the effectiveness of whole brain radiotherapy followed by stereotactic radiotherapy for newly diagnosed brain metastasis.
MATERIALS AND METHODS
Thirty-three metastatic brain tumors received radiotherapy to the whole brain and stereotactic radiotherapy in 25 patients. Lung carcinomas were the most common (17/25) primary tumor. The radiation dose was 30 to 40 Gy for the whole brain, with a 12 to 40 Gy boost to the metastatic foci. Survival and local control rates were determined, and the prognostic factors for survival were evaluated.
RESULTS
The overall median survival was 15 months and the actuarial survivals at 1- and 2-year were 67% and 31%, respectively. The local tumor control rate was 79%, with a median follow-up period of 9 months (2~36 months). The prognostic factors associated with survival were age, tumor size and the existence of active extracranial metastasis, with the performance status showing marginal significance. No acute or chronic complications were observed in the patients.
CONCLUSION
From our data, cranial radiotherapy followed by stereotactic radiotherapy was useful in the local control of metastatic tumors, and in the survival of patients with tumor factors, such as small size or the absence of extracranial tumor activity, and host factors, such as young age or good performance status.

Citations

Citations to this article as recorded by

Prognostic Factors and Survival Outcome of Whole Brain Radiotherapy in Metastatic Brain Cancer- A Single Regional Cancer Centre Experience in North India
Purnima Thakur, Aman Sharma, Manish Gupta, Anupama Dhiman, Jyoti Sharma
Journal of Evolution of Medical and Dental Sciences.2019; 8(43): 3206. CrossRef
Clinical outcome of central nervous system metastases from breast cancer: differences in survival depending on systemic treatment
Hee-Jun Kim, Seock-Ah Im, Bhumsuk Keam, Yu-Jung Kim, Sae-Won Han, Tae Min Kim, Do-Youn Oh, Jee Hyun Kim, Se-Hoon Lee, Eui Kyu Chie, Wonshik Han, Dong-Wan Kim, Tae-You Kim, Dong-Young Noh, Dae Seog Heo, In Ae Park, Yung-Jue Bang, Sung Whan Ha
Journal of Neuro-Oncology.2012; 106(2): 303. CrossRef

4,125 View
27 Download
2 Crossref

The Outcome of Philadelphia Chromosome-Positive Adult ALL: Characteristics and Prognosis: Hun Ho Song, Je Hwan Lee, Byung Min Jeon, Jung Hee Lee, Eul Ju Seo, Chan Jeoung Park, Hyun Sook Chi, Jung Shin Lee, Woo Kun Kim, Kyoo Hyung Lee; Cancer Res Treat. 2002;34(4):289-295. Published online August 31, 2002; DOI: https://doi.org/10.4143/crt.2002.34.4.289

Abstract PDF

The Philadelphia (Ph) chromosome is a well- known chromosome abnormality in adults with B-lineage ALL, and is associated with a poor prognosis. This study compared the clinical manifestations and prognosis in adult Ph-positive and Ph-negative ALL patients.
MATERIALS AND METHODS
We retrospectively analyzed the clinical records of adult patients newly diagnosed as B-lineage ALL, between January 1995 and February 2001. Fifty five patients were included in this study. We divided the patients into Ph-positive and Ph-negative groups.
RESULTS
Eighteen of the 55 patients (32.7%) were found to have the Ph chromosome. At initial diagnosis, the Ph-positive patients had higher circulating leukocyte counts, lower platelet counts and had a greater tendency to bleed, than the Ph-negative group. The complete remission rates were 83.3% and 83.8% for the Ph-positive and the Ph-negative groups, respectively. Four of the Ph-positive, and 13 of the Ph-negative, patients underwent allogenic bone marrow transplantation. The median follow-up for the surviving patients was 39.3 months. The three-year survival rates were 10.4% and 51.8% for the Ph-positive and the Ph-negative groups, respectively. The median disease-free survival was 7.7 months for the Ph-positive group, but did not reach the median value in the Ph-negative group. Among the Ph-positive patients, age was the only factor that had an impact on the disease outcome.
CONCLUSION
In adult B-lineage ALL, the Ph-positive patients had similar complete remission rates to other patients; however, the remission was of shorter duration, with a higher relapse rate in the Ph-positive patients. More effective treatments are needed to improve the survival of the Ph-positive patients.

Citations

Citations to this article as recorded by

Long‐term follow‐up of imatinib plus combination chemotherapy in patients with newly diagnosed Philadelphia chromosome‐positive acute lymphoblastic leukemia
Sung‐Nam Lim, Young‐Don Joo, Kyoo‐Hyung Lee, Dae‐Young Kim, Je‐Hwan Lee, Jung‐Hee Lee, Hyun‐Sook Chi, Sung‐Cheol Yun, Won Sik Lee, Sang Min Lee, Seonyang Park, Inho Kim, Sang Kyun Sohn, Joon Ho Moon, Hun‐Mo Ryoo, Sung Hwa Bae, Myung Soo Hyun, Min Kyoung K
American Journal of Hematology.2015; 90(11): 1013. CrossRef
Clinical effect of imatinib added to intensive combination chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia
K-H Lee, J-H Lee, S-J Choi, J-H Lee, M Seol, Y-S Lee, W-K Kim, J-S Lee, E-J Seo, S Jang, C-J Park, H-S Chi
Leukemia.2005; 19(9): 1509. CrossRef

4,212 View
21 Download
2 Crossref

5-Fluorouracil and Cisplatin (FP) with Concurrent Radiotherapy for Locally Advanced Head and Neck Cancer: Hyoung Sam Kim, Ki Seok Kim, Sang Seok Bea, Seok Jin Oh, Ki Hyeong Lee, Won Dong Kim, Woo Yoon Park, Seung Taik Kim; Cancer Res Treat. 2002;34(4):296-301. Published online August 31, 2002; DOI: https://doi.org/10.4143/crt.2002.34.4.296

Abstract PDF

The combination of chemotherapy and radiotherapy is emerging as the new standard modality for the treatment of locally advanced head and neck cancer, due to the inherent functional and cosmetic sequelae associated with its surgical management. Combination chemotherapy with 5-fluorouracil and cisplatin (FP) is one of the most active regimens for the head and neck cancer. Furthermore, both agents are known to act as radiosensitizer. This study was conducted to determine the efficacy, feasibility, and the toxicities of concurrent FP chemotherapy with radiotherapy.
MATERIALS AND METHODS
Patients with histologically proven locally advanced head and neck cancer (T3-4 or node positive) were enrolled in the study. Patients received 5-fluorouracil, 1,000 mg/m2/day, continuously for 4 days, and cisplatin, 75 mg/m2, on day 1. This regimen was given every four weeks. The radiotherapy (45 Gy) was started on day 1 of the first cycle, and administered in 25 fractions. Following a three-week interval, the radiotherapy was resumed on day 1 of the third cycle of chemotherapy, and administered in 15 fractions (27 Gy).
RESULTS
Of the 31 eligible patients included, 28 were able to be evaluated for the tumor response. The response rate for the 28 patients was 93% (16 complete responses, 10 partial responses). Disease free survival for the 16 complete responders was 37 months (median, 1 ~41 months), with a median follow-up time of 31 months. The 1-, 2-, and 3-year survival rates were 82%, 69%, and 63%, respectively. Regarding the feasibility of this treatments, only nineteen patients (61%) received the complete courses of scheduled treatments. The median duration of admission for all patients was 39 days. Grade 3 or 4 stomatitis were observed in 25 patients (83%) and appeared as the dose limiting toxicity of this regimen CONCLUSION: Although FP chemotherapy with concurrent radiotherapy is toxic, it is an effective and relatively feasible treatment for locally advanced head and neck cancer. The majority of patients experienced severe stomatitis, which appeared as the dose limiting toxicity of this regimen.

Citations

Citations to this article as recorded by

Chemotherapy of Head and Neck Cancer
Chang Ki Yeo
Korean Journal of Otorhinolaryngology-Head and Neck Surgery.2014; 57(5): 291. CrossRef

4,991 View
32 Download
1 Crossref

Suppression of Peritoneal Metastases by Expression of Murine Endostatin cDNA: Seung Ho Choi, Jae Hoon Lee, Sung Hee Hong, Woo Jin Hyung, Sung Hoon Noh, Hyun Cheol Chung, Jae Kyung Roh, Jin Sik Min; Cancer Res Treat. 2002;34(4):302-307. Published online August 31, 2002; DOI: https://doi.org/10.4143/crt.2002.34.4.302

Abstract PDF

Peritoneal seeding is one of problems to be solved in gastrointestinal and ovarian cancers. Angiogenesis is the critical step for a dormancy tumor cluster to be an overt metastatic nodule. However, whether an anti-angiogenesis strategy is effective in the control of peritoneal metastases is still obscure. In this study, we evaluated whether endostatin, an endogenous angiogenesis inhibitor, suppresses peritoneal metastases.
MATERIALS AND METHODS
We transduced a human gastric cancer cell line, AGS and a murine renal cancer cell line, Renca, with the plasmid pEndoSTHB, which encodes a secretable form of murine endostatin. Endostatin expression was tested with western blotting, and the biological activity of the secreted endostatin was confirmed with in vitro endothelial cell growth inhibition. In the animal experiments, stable transfectants were injected intraperitoneally.
RESULTS
We demonstrated secretion of endostatin from two cell lines transduced with the plasmid pEndoSTHB. Conditioned media secreted from pEndoSTSB-transduced mammalian cells were shown to potently inhibit endothelial cell growth in vitro. We selected stable transfectants with similar in vitro growth rates of their parental cell lines. Significant tumor growth inhibition was observed in the endostatin-expressing Renca cells intraperitoneal injection group at days of 28, compared to the null transfectants intraperitoneal injection control group.
CONCLUSION
These results support that peritoneal seeding is angiogenesis-dependant and an anti-angiogenesis strategy is a good way to control peritoneal metastases.

Citations

Citations to this article as recorded by

The kringle domain of tissue-type plasminogen activator inhibits in vivo tumor growth
Byoung-Shik Shim, Byoung-Hak Kang, Yong-Kil Hong, Hyun-Kyung Kim, Il-Ha Lee, Soo-Young Lee, Young-Joon Lee, Suk-Keun Lee, Young Ae Joe
Biochemical and Biophysical Research Communications.2005; 327(4): 1155. CrossRef

4,310 View
22 Download
1 Crossref

Arsenic Trioxide Induces Apoptosis of HL-60 Cells via Activation of Intrinsic Caspase Protease with Mitochondrial Dysfunction: Byung Hak Jung, Channy Park, Hak Ryul Kim, Moo Rim Park; Cancer Res Treat. 2002;34(4):308-315. Published online August 31, 2002; DOI: https://doi.org/10.4143/crt.2002.34.4.308

Abstract PDF

Arsenic trioxide (As2O3) was introduced into the treatment of refractory or relapsed acute promyelocytic leukemia and showed a striking effectiveness in China and United States multicenter study. However, the mechanistic basis for the carcinogenic or therapeutic effects of arsenics is still poorly understood. So, this study is performed to determine whether As2O3 induces apoptosis through intrinsic caspase cascades in acute promyelocytic leukemia HL-60 cells.
MATERIALS AND METHODS
HL-60 cells were treated with As2O3 to investigate apoptosis through signaling of caspase cascades and mitochondrial dysfunction.
RESULTS
As2O3 (>0.5 uM) decreased the viability of HL-60 cells in a dose-dependent manner, which was revealed as apoptosis shown chromatin condensation and ladder pattern DNA fragmentation. As2O3 increased the catalytic activity of caspase family cysteine proteases including caspase-3 and -9 proteases. Consistently, PARP, an intracellular biosubstrate of caspase-3 protease, was cleaved from 116 kDa to 85 kDa fragments. It also induced the change of mitochondrial membrane potential. Morever, As2O3 resulted in the increase of Bak.
CONCLUSION
These data suggest that As2O3 induces apoptosis of HL-60 cells through activation of intrinsic caspase protease with mitochondrial dysfunction.

Citations

Citations to this article as recorded by

The Time‐Dependent Serial Gene Response to Zeocin Treatment Involves Caspase‐Dependent Apoptosis in HeLa Cells
Jooyeon Hwang, Young‐Youl Kim, Sungjin Huh, Junghee Shim, Chan Park, Kuchan Kimm, Dong Kug Choi, Tae‐Kyu Park, Soonhag Kim
Microbiology and Immunology.2005; 49(4): 331. CrossRef

3,522 View
21 Download
1 Crossref

First
Prev
Page of 1
Next
Last

Previous issues